Last 36 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.64 | 56.26 | 55.42 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -96.3% | -46.5% | +27.8% | |
| P/B Ratio | 21.93 | 28.31 | 22.67 | 20.58 | 17.29 | 17.11 | 11.51 | 11.71 | 9.82 | 6.04 | 9.32 | 6.34 | 3.41 | 2.98 | 2.79 | 1.80 | 1.87 | 0.69 | 2.82 | 5.30 | 6.47 |
| — | +65.4% | +96.9% | +75.8% | +76.1% | +183.5% | +23.5% | +84.6% | +187.6% | +102.3% | +234.5% | +252.9% | +82.1% | +330.2% | -1.2% | -66.1% | -71.0% | -85.8% | -63.2% | -4.4% | -22.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 11.5% | -617.5% | -472.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +103.0% | -15.7% | +6.6% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -20.9% | -873.4% | -678.6% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +96.4% | -15.0% | +12.7% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -24.0% | -887.0% | -686.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +95.9% | -14.7% | +11.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -123.1% | -41.5% | -40.5% | -37.1% | -42.7% | -40.3% | -21.9% | -29.7% | -60.6% | -37.0% | -27.9% | -23.5% | -22.9% | -17.6% | -16.1% | -14.2% | -13.9% | -17.6% | -4.6% | -20.0% | -18.6% |
| — | -2.9% | -84.4% | -25.0% | +29.5% | -9.1% | +21.3% | -26.4% | -164.8% | -110.2% | -73.0% | -65.5% | -64.6% | -0.1% | -247.9% | +29.0% | +25.1% | -30.8% | +58.1% | -21.8% | +42.8% | |
| ROA | -86.0% | -20.8% | -22.5% | -22.3% | -27.2% | -29.4% | -16.9% | -20.3% | -31.8% | -23.7% | -19.7% | -16.4% | -15.8% | -12.6% | -11.7% | -10.5% | -10.6% | -12.8% | -2.8% | -11.9% | -11.9% |
| — | +29.5% | -32.6% | -9.7% | +14.4% | -24.3% | +13.9% | -23.7% | -100.8% | -87.2% | -68.0% | -56.6% | -48.8% | +0.8% | -319.9% | +12.0% | +10.6% | -43.8% | +62.3% | -23.7% | +19.3% | |
| ROIC | -201.2% | -227.9% | -186.6% | -139.0% | -73.9% | -44.3% | -23.4% | -32.0% | -52.8% | -33.6% | -26.1% | -20.7% | -20.3% | -19.2% | -16.4% | -13.0% | -19.0% | -23.8% | -5.3% | -48.9% | -42.8% |
| — | -414.3% | -696.1% | -334.6% | -39.9% | -31.8% | +10.1% | -54.8% | -160.9% | -74.8% | -59.3% | -59.0% | -6.5% | +19.2% | -211.6% | +73.4% | +55.6% | -6.1% | +62.1% | -146.1% | +86.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.80 | 0.75 | 0.44 | 0.45 | 0.26 | 0.20 | 0.18 | 0.84 | 0.56 | 0.33 | 0.27 | 0.38 | 0.32 | 0.30 | 0.27 | 0.27 | 0.25 | 0.49 | 0.49 | 0.29 |
| — | +204.5% | +268.6% | +151.1% | -46.6% | -52.5% | -38.5% | -35.6% | +122.1% | +72.0% | +11.4% | +2.9% | +38.4% | +30.2% | -39.1% | -45.7% | -4.6% | -3.0% | +109.3% | +124.0% | -45.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.95 | 7.02 | 8.64 | 6.95 | 6.30 | 6.33 | 10.25 | 9.61 | 3.88 | 6.04 | 6.58 | 8.80 | 8.55 | 10.70 | 10.96 | 9.01 | 10.60 | 9.69 | 6.85 | 4.13 | 4.00 |
| — | +11.0% | -15.7% | -27.7% | +62.3% | +4.8% | +55.7% | +9.2% | -54.6% | -43.6% | -39.9% | -2.4% | -19.4% | +10.5% | +60.0% | +118.5% | +165.3% | +123.6% | +50.4% | -49.0% | +10.0% | |
| Quick Ratio | 6.95 | 7.02 | 8.64 | 6.95 | 6.30 | 6.33 | 10.25 | 9.61 | 3.88 | 6.04 | 6.58 | 8.80 | 8.55 | 10.70 | 10.96 | 9.01 | 10.60 | 9.69 | 6.85 | 4.13 | 4.00 |
| — | +11.0% | -15.7% | -27.7% | +62.3% | +4.8% | +55.7% | +9.2% | -54.6% | -43.6% | -39.9% | -2.4% | -19.4% | +10.5% | +60.0% | +118.5% | +165.3% | +123.6% | +50.4% | -49.0% | +10.0% | |
| Interest Coverage | -53.83 | -23.32 | -44.83 | -34.90 | -75.63 | -90.24 | — | — | — | — | — | — | — | — | — | — | — | -51.58 | -6.82 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SRRK stock.
Scholar Rock Holding Corporation's current P/E is -15.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Scholar Rock Holding Corporation's business trajectory between earnings reports.